Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated | ARWR Message Board Posts


Arrowhead Pharmaceuticals, Inc.

  ARWR website

ARWR   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  10009 of 10176  at  6/18/2019 3:02:43 PM  by

evernewbliss


 In response to msg 10007 by  Aspector
view thread

Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA

I think ANG3 and PCSK9 will address different segments of the market. PCSK9 will be preferred where you need to only lower LDL. ANG3 will be preferred where there is need to lower both LDL and TG. Negative of ANG3 is that it doesnt only reduce LDL, but it also reduces HDL by the same percentage. So the ration between LDL/HDL doesnt change. It would take Head to Head outcome trial between PCSK9 and ANG3 to convince physicians that lowering of HDL is not an issue.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4  
   Views: 290 []
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...